Monitor the upcoming stockholder meeting for approval of the conversion of Series B and Series C Preferred Stock, which would massively dilute current common shareholders (over 157 million potential new shares). The outcome will determine the future ownership structure and board composition, with Fairmount affiliates gaining four of five board seats upon conversion approval.
Price Chart
Executive Summary
Fairmount Funds Management LLC and affiliates have filed a Schedule 13D disclosing beneficial ownership of 19.99% of Alaunos Therapeutics (TCRT) common stock following the October 13, 2026 reverse merger with Velaris Therapeutics and a concurrent $350 million PIPE financing. The filing details the merger structure, the issuance of convertible preferred stock with a 19.99% beneficial ownership limitation, and the appointment of Fairmount's Peter Harwin to the board. This is a post-closing disclosure of a pre-arranged transaction, not a new activist campaign.
Key Financial Metrics
Key Facts
- Fairmount Funds Management LLC and affiliates beneficially own 858,789 shares of common stock (19.99% of outstanding) as of October 13, 2026.
- The stake includes 687,789 shares of common stock and 171,000 shares issuable upon conversion of Series C Preferred Stock, all held by Fairmount Healthcare Co-Invest VII L.P.
- The aggregate purchase price for the common stock, Series B Preferred Stock, and Series C Preferred Stock is $100,199,073.47.
- The filing is a mandatory disclosure following the October 13, 2026 reverse merger with Velaris Therapeutics and a concurrent $350 million PIPE financing.
- Peter Harwin of Fairmount serves on the board of directors of Alaunos Therapeutics.
- The Series B and Series C Preferred Stock are convertible into common stock at a 1,000:1 ratio, subject to a 19.99% beneficial ownership limitation that reduces to 9.99% if Fairmount's ownership falls to 9.0% or less.
- The merger agreement requires stockholder approval for full conversion of the preferred stock, a name change to 'Velaris Therapeutics, Inc.', a reverse stock split, and an increase in authorized shares.
Financial Impact
Fairmount and affiliates paid $100,199,073.47 for their combined stake. The PIPE financing raised approximately $350 million in aggregate.
Risk Factors
- Massive potential dilution: conversion of all outstanding Series B and Series C Preferred Stock would add over 157 million common shares, overwhelming the current ~4.1 million share base.
- Stockholder vote on conversion proposal and reverse stock split introduces binary event risk; failure could delay or alter the merger's intended structure.
- The 180-day lock-up agreements limit selling by insiders and major holders, but the resale registration statement filing within 30 days could lead to a near-term overhang once effective.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D Filing (Primary) | 0001683168-26-007898 |
| Document: 0001683168-26-007898-index-headers.html | 0001683168-26-007898 |
| Document: 0001683168-26-007898-index.html | 0001683168-26-007898 |
| Document: 0001683168-26-007898.txt | 0001683168-26-007898 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.39 | awaiting T+20 | — | $1.94 (−18.75%) |
Oct 21, 2026 5d ago | 8-K | $3.04 | awaiting T+20 | — | $1.94 (−36.18%) |
Oct 15, 2026 11d ago | SC 13D/A | $2.63 | awaiting T+20 | — | $1.94 (−26.24%) |
Oct 15, 2026 11d ago | SC 13D | $2.63 | awaiting T+20 | — | $1.94 (−26.24%) |
Oct 13, 2026 14d ago | Press Release | $3.03 | awaiting T+20 | — | $1.94 (−35.97%) |
Oct 13, 2026 14d ago | 8-K | $3.03 | awaiting T+20 | — | $1.94 (−35.97%) |
Oct 9, 2026 17d ago | 8-K | $1.05 | awaiting T+20 | — | $1.94 (−84.76%) |
Sep 18, 2026 5w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $1.94 (−61.67%) |
Sep 16, 2026 5w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $1.94 (+21.25%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $1.94 (−18.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers